


7801840

教师阅览室

SELECTED PAPERS  
ON  
PLANNED  
PARENTHOOD

计 划 生 育 专 题 论 文 选 集



VOLUME

3

Intrauterine and  
Other Contraceptive Devices

宫内节育器及其它避孕器

2109-53  
7E801-53  
3  
3  
781

7801840



~~3664~~

3662

Selected Papers on Planned Parenthood

Vol. 3

**Intrauterine & Other  
Contraceptive Devices**



March 1975

# THE ONLY 5-YEAR STUDY IN AN ENTIRE STATE FOR SAFETY AND EFFECTIVENESS OF AN IUD

USE-EFFECTIVENESS OF SAF-T-COIL FOUND COMPARABLE TO THE "PILL" BASED ON 27,712 INSERTIONS AND 541,248 WOMAN-MONTHS OF EXPOSURE.

Definitive report from Florida (based on results from 67 clinics).

## SAF-T-COIL®

**"Our extensive experience with the various IUDs to date induced us to make the double-coil the device of first choice in our clinics...."**

This was the conclusion of a five-year evaluation of Saf-T-Coil in 67 Florida clinics, based on nearly 28,000 insertions and over a half million woman-months of exposure.<sup>1</sup> The clinical evaluation proves one IUD is found comparable to the "pill" in use-effectiveness and is safe.

### Study Findings:

**Pregnancy rate in situ** ... 0.8%

**Continuation rate** ... 80% (the continuation rate rose from 75% to a high 80% as doctors gained experience in inserting the device.)

### Saf-T-Coil's 88% continuation rate and low pregnancy rate confirmed in private patients

Another investigator, in private practice, found Saf-T-Coil to have an even lower pregnancy rate *in situ*—0.42%, and a higher continuation rate—88% for the first year. In the second year, representing 4,360 woman-months of use, the continuation rate remained high—81.5% with the continuation of the same low pregnancy rate of 0.42%. His conclusion: Saf-T-Coil "... compares favorably to the oral contraceptive..."<sup>2</sup>

Saf-T-Coil effectiveness—confirmed!

**Saf-T-Coil Nullip "represents a milestone in achievement in the field of intrauterine devices."**<sup>1</sup>

In a six-month preliminary evaluation of 273 patients,

representing an estimated 819 woman-months of us

No pregnancies reported

High continuation rate: 91.2%

Low expulsion rate: 4.5%; low removal rate 4.3%

No patient discomfort, easy insertion, no postinsertion syncope noted

### A safe, effective Saf-T-Coil for almost every patient

There's a Saf-T-Coil for almost every patient (32-S, 33-S and Nullip 25-S) to provide her with a safe and comfortable contraceptive through all her reproductive years. And with every Saf-T-Coil—Saf-T-Sound®—the sterile, disposable intrauterine probe to help make fitting easier and more accurate.

**Caution:** Federal law restricts sale by or on the order of a physician.

**Contraindications:** Should not be used in pregnancy or suspicion of pregnancy, suspicion of carcinoma, acute cervicitis, acute or subacute adnexal disease, fibroids, menorrhagia or unexplained bleeding.

1. Caraway, A. F. and Vaughn, B. J.: J. Reprod. Med. 10: 171, April 1973.

2. Hayes, O. J.: South. Med. J. 66: 254, Feb. 1973.

**Sterile**

## SAF-T-COIL®

For:  
effect



英5-1/N1661-3  
计划生育专题论文选集  
第3卷  
¥1.60

N60/1661-3

## CONTENTS

### Reviews

#### 综 述 评 论

Intrauterine Contraception .....	2
----------------------------------	---

#### 宫内避孕

(*American Journal of Obstetrics & Gynecology*, V. 112, N. 7,  
p. 1000-1023, 1972)

Recent Developments with Intra-Uterine Devices .....	27
--	----

#### 宫内节育器应用的现代进展

(*Contraception*, V. 8, N. 2, p. 99-112, 1973)

Mechanisms of Action of Intra-uterine Contraceptive Devices in Women & Other Mammals .....	42
---	----

#### 在妇女及其它哺乳类中宫内节育器的作用机制

(*British Medical Bulletin*, V. 26, N. 1, p. 52-59, 1970)

### Copper T Intrauterine Contraceptive Devices

#### 含铜 T 形宫内节育器

Metallic Copper As An Intrauterine Contraceptive Agent .....	52
--	----

#### 金属铜作为宫内避孕剂

(*American Journal of Obstetrics & Gynecology*, V. 117, N. 5,  
p. 602-618, 1973)

A Study of the Copper T Intrauterine Contraceptive Device (TCu 200) in Nulliparous Women .....	70
---	----

#### 未产妇女放置含铜 200 T 形宫内节育器的研究

(*American Journal of Obstetrics & Gynecology*, V. 116, N. 8,  
p. 1092-1096, 1973)

Two Years Experience with Copper-T 200 in A Swedish Population—A Comparison Between Nulliparous & Parous Women.....	75
--	----

#### 含铜 200 T 形宫内节育器在瑞典妇女中的应用——未产妇和已产妇的比较

(*Contraception*, V. 10, N. 1, p. 55-61, 1974)

The TCu-300 IUD .....	83
-----------------------	----

#### 含铜 300 T 形宫内节育器

(*International Journal of Fertility*, V. 18, N. 3, p. 185-187, 1973)

Experience with Three Different Models of the Copper T Intrauterine Contraceptive Device in Nulliparous Women .....	86
三种不同类形的含铜 T 形宫内节育器在未产妇中的应用效果	
(American Journal of Obstetrics & Gynecology, V. 119, N. 3, p. 414-417, 1974)	
The Anchoring Mechanism of Retention of the Copper T Device .....	91
含铜 T 形宫内节育器的固定机制	
(Fertility & Sterility, V. 24, N. 3, p. 165-169, 1973)	
Copper Levels in Cervical Mucus of Women with Copper-Bearing & Noncopper-Bearing Intrauterine Devices .....	97
使用含铜与不含铜的宫内节育器后,妇女宫颈粘液中含铜水平的比较	
(Biology of Reproduction, V. 8, N. 4, p. 499-503, 1973)	
Intrauterine Contraception with the Copper 7 Device .....	103
含铜“7”型宫内节育器	
(Acta Europaea Fertilitatis, V. 5, N. 1, p. 1-24, 1974)	
<b>Other Types of Intrauterine Contraceptive Devices</b>	
其它类型的宫内节育器	
Intrauterine Adhesions: A Syndrome of the Past with the Use of the Massouras Duck's Foot No. 2 Intrauterine Contraceptive Device.....	128
Massouras 鸭爪型 2 号宫内节育器对宫内粘连综合症的作用	
(American Journal of Obstetrics & Gynecology, V. 116, N. 4, p. 576-578, 1973)	
Experience with the Dalkon Shield As A Contraceptive Device.....	131
用 Dalkon 盾作为宫内节育器的效果	
(Obstetrics & Gynecology, V. 43, N. 3, p. 443-446, 1974)	
<b>Intrauterine Devices with Releasing drugs</b>	
带有缓释药物的宫内节育器	
Fertility Control by Intrauterine Release of Progesterone .....	137
用黄体的宫内缓释来控制生育	
(Obstetrics & Gynecology, V. 43, N. 5, p. 769-779, 1974)	
The IUD and Prostaglandins: A Review of the Evidence .....	149
宫内节育器与前列腺素: 对实验资料的评论	
(Obstetrics & Gynecology, V. 42, N. 4, p. 617-620, 1973)	
Experience with A Fluid-Filled Intrauterine Device .....	153
灌液型宫内节育器	
(Obstetrics & Gynecology, V. 43, N. 1, p. 81-86, 1974)	

## Side Effects & Thier Therapeutics

### 副作用及其治疗

- Serum Immunoglobulin Levels in Women Using Intrauterine Contraceptive Devices ..... 161  
妇女放置宫内节育器后血清免疫球蛋白的水平  
(*The Journal of Obstetrics & Gynaecology of the British Commonwealth*, V. 81, N. 2, p. 155-159, 1974)
- Comparative Quantitation of Menstrual Blood Loss with the Lippes Loop, Dalkon Shield, & Copper T Intrauterine Devices..... 167  
放置 Lippes 氏环, Dolkon 氏盾及含铜 T 形宫内节育器后月经失血量的比较  
(*Contraception*, V. 10, N. 1, p. 63-71, 1974)
- Antifibrinolytic Control of Menorrhagia after IUD Insertion ..... 177  
用抗纤维蛋白溶酶来控制装入宫内节育器后的月经过多  
(*The Practitioner*, V. 210, N. 1257, p. 417-420, 1973)
- The in Situ IUD & Pregnancy Outcome..... 182  
带宫内节育器时受孕的后果  
(*American Journal of Obstetrics & Gynecology*, V 119, N. 1, p. 124-130, 1974)

## Intracervical & Vaginal Devices

### 子宫颈内与阴道内的节育器

- Antifertility Effects of An Intracervical Progestational Device ..... 190  
宫颈管内放置孕激素节育器的抗生育效果  
(*Biology of Reproduction*, V. 7, N. 2, p. 160-165, 1972)
- Physiological Aspects of Vaginal Contraception: A Review ..... 197  
阴道避孕的生理学概念: 综述  
(*Contraception*, V. 9, N. 4, p. 333-345, 1974)
- Inhibition of Ovulation with Cyclic Use of Progestogen-Impregnated Intra-vaginal Devices ..... 211  
周期性应用浸透孕激素的阴道节育器来抑制排卵  
(*American Journal of Obstetrics & Gynecology*, V. 113, N. 7, p. 927-932, 1972)

## Abstracts

### 摘 要

#### Intrauterine Contraception

##### 宫内避孕

2

作者用人的各个发育时期作譬喻,较形象地综述了宫内节育器的发展过程。

(1) 宫内节育器的“胚胎期”: 早期记载骆驼过沙漠时,安置石头于子宫内以防止受孕。

(2) 宫内节育器的“婴儿期”: 1928 年开始临床初步试用的环型,因保守思想使宫内避孕技术的进展至少停滞 30 年。

(3) 宫内节育器的“童年期”: 1959 年公布临床经验,重新推广应用。

(4) 宫内节育器的“青春期”: 发展迅速。1962 年开展研究计划并对宫内节育器的各种形状、大小和材料进行评定。共同缺点是不能使宫腔适应节育器的形状。

(5) 宫内节育器的“发身期”: 1968—1969 年从改进宫内节育器的形状和大小着手,以减少宫腔的变形。

(6) 宫内节育器的“成熟期”: 宫内节育器含有缓释的有效抗生育制剂,例如金属铜和孕激素等。

介绍了未产妇和未孕妇女宫腔内节育器的实际应用和流产后立即装置节育器的效应。

详细讨论了惰性和活性宫内节育器的作用机制。

#### Recent Developments with Intra-uterine Devices

27

##### 宫内节育器应用的现代进展

由于应用已有的宫内节育器所发生的副作用,促使了“第二代”节育器的产生与发展。本研究的目的是从修改的原则和所引起的作用方面来评论这些新避孕器的发展。介绍了改变旧的“惰性”节育器的大小和形状以及新型“附着药品”的节育器。讨论了关于这些“第二代”节育器的作用效能和副作用。

#### Mechanisms of Action of Intra-uterine Contraceptive Devices in Women & Other Mammals

42

##### 在妇女和其他哺乳动物中宫内节育器的作用机制

本文综述了宫内节育器在各种哺乳动物中生物效应的实验结果。主要课题是讨论所观察到的关于宫内节育器作用机制的效果,着重对妇女和灵长动物的实验进行探讨。所讨论的作用机制分下列几方面:机械性的干扰;炎症的作用;子宫内黏膜组织学上的变化、成熟程度和对激素的敏感性;宫腔液体中的生物化学变化;对黄体的作用;对子宫活动的影响等。除了以上所提供的主要作用以外,还不能排除宫内节育器的其他辅助作用,总的抗生育作用是由多种因素的综合结果。似乎可以合理地认为宫内节育器的作用是发生在着床之前,因此节育器的抗生育作用不属于流产一类。

#### Metallic Copper As An Intrauterine Contraceptive Agent

52

##### 金属铜作为子宫腔内的避孕剂

本文综述了铜与生育过程有关的生物学方面的资料。包括当宫腔装置有金属铜或把它取出后影响子宫内黏膜,宫内液体,宫颈粘液和血清内铜浓度的周期性变化,以及内膜里几种酶的变化。论述了含铜T形宫内节育器在体内铜的消失速度,这些资料是结合宫腔抗生育作用有效时间来考虑的;另外从理论上考虑到所用铜的剂量与全身铜代谢平衡的关系。特别提到威尔逊病。描述了在宫腔内铜丝表面可能发生的变化。介绍了从恒河猴实验中收集的资料,关于铜碎片可能引起的问题。介绍最近各国有关T铜200和300型的应用效能的临床资料,并初步报导了应用9个月T铜200和铜7型对照的结果。

#### A Study of the Copper T Intrauterine Contraceptive Device (TCu 200) in Nulliparous Women

70

##### 未产妇女放置含铜200T形宫内节育器的研究

T铜200型宫内节育器,是一种非常适合于未产妇女避孕用的器具。作者对471例未产妇进行观察,发现可不使用麻醉进行放置,并于术后使用极少量止痛剂。在26个月期间,共积累了6,044妇女月的资料。作者对放置满一年的4,430妇女月的资料进行了第一阶段

的统计,其结果为:妊娠率 1.7%,脱落率 5.4%,由于出血或疼痛而取除者占 10.7%。上述发生率低于未产妇用其他类型的宫内节育器;作者认为这样的结果接近于经产妇使用 T 铜 200 或其他类型的宫内节育器的发生率。一年的继续使用率为 74.2%,说明 T 铜 宫内节育器适用于未产妇,是一种可以取代口服避孕药的有效避孕方法。

## Two Years Experience with Copper-T 200 in A Swedish Population Comparison between Nulliparous & Parous Women 75

### 含铜 200 T 形宫内节育器在瑞典妇女中的应用(未产妇和经产妇之间的比较)

本研究的目的是为了确定 T 铜 200 节育器应用在经产妇时是否能和未产妇一样作为一种合适的避孕方法。

在瑞典居民中选 750 位病员,分为未产妇和经产妇二组,经过两年应用的研究,共观察了 11,284 月。其结果说明,这一装置对经产妇和未产妇两者都是一种良好的避孕方法。受孕率低,很受欢迎。

## The TCU-300 IUD

### 含铜 300 T 形宫内节育器

83

本文初步报导了 Werstern 妇产科诊所应用表面积 300 mm<sup>2</sup> 铜丝塑料 T 型节育器在 211 人, 739 累计月中临床应用的结果。这项研究的设计是为了对这种节育器效果作出估价。从铜丝表面积与累计的妊娠率的关系曲线来看,增加表面积能减少妊娠率,但表面积超过 300 mm<sup>2</sup> 以上,效果的提高就不明显了。文内介绍的材料和方法基本上与表面积 200 mm<sup>2</sup> 铜丝的 T 形节育器相似,所不同的是铜丝表面积为 300 mm<sup>2</sup>,重量为 190 mg。文内又讨论了 T 铜 200 和 T 铜 300 每天失铜的情况。在使用 739 累计月中有妊娠 4 例,脱落 4 例,因医疗原因取出的 15 例,其中因出血和疼痛 7 例,宫颈穿孔 2 例。

结论: T 铜-300 的初步试验证明具有低的妊娠率和高继续放置率。

## Experience with 3 Different Models of the Copper T Intrauterine Contraceptive Device in Nulliparous Women 86

### 三种不同类型的含铜 T 形宫内节育器在未产妇中的应用效果

含铜 T 形宫内节育器被认为是未产妇的有效避孕措施,并估计节育器上含铜量的增多会使受孕率下降。

在门诊按自愿选择 T 铜的未产妇中,分期顺序用 T 铜 200,300 和 380 节育器加以比较,一年后用 Life Table 方法进行分析第一阶段的情况。结果提示增加铜减低了受孕率,而不增加脱落率及因流血或疼痛的取出率。还应进行一次无选择性的试验以确定本研究所观察到的趋向是否正确。

## The Anchoring Mechanism of Retention of the Copper T Device

### 含铜 T 形宫内节育器的固定机制

91

本文介绍了安放含铜 T 形宫内节育器者 40 例,其中 39 例用子宫输卵管造影来估计 T 铜与子宫腔之间的空间关系。在放置 1—3 月内: 1 例受孕(未做子宫输卵管造影), 3 例出现流血和 1 例脱落。其余没有症状。39 例中 37 例显示“T”的一端或两端穿进子宫壁。作者们认为这样可以引起“固定的机转”,避免脱落的发生。

## Copper Levels in Cervical Mucus of Women with Copper-Bearing & Noncopper-Bearing Intrauterine Devices 97

### 使用含铜和不含铜宫内节育器后妇女宫颈粘液中含铜水平的比较

本文报导了含铜宫内节育器和塑料宫内节育器的使用者月经各期中宫颈粘液铜含量变化的测定各 50 例,并和正常妇女作比较,发现二种宫内节育器使用者在月经中期的铜含量最低,这和对照组是一致的。又发现不论是含铜的、还是不含铜的宫内节育器使用者在月经各期中(特别是放置后 7 周以内)铜的含量都比对照组高,而含铜的宫内节育器使用者为最高。但随着使用时间的延长(7 周以上)含铜宫内节育器使用者的铜含量就降低到塑料节育器的水平了。

## Intrauterine Contraception with the Copper 7 Device

### 含铜“7”形宫内节育器

103

本文报导动物实验中,如在胚囊着床前,在子宫腔内放置铜丝则有避孕作用。这个作用是局部的,主要是铜离子对子宫内膜所起的反应。从人体和动物实验中观察到内膜反应是

可逆的。在雄鼠的输精管(Deferent Duct)中放置铜丝后,98.3% 精管中精子的成熟遭到抑制。有报导证明在子宫颈管内放入铜丝,也有杀精作用。

作者介绍了含铜“7”形宫内节育器的结构和放置方法,并将各种类型的铜丝节育器的疗效作了比较。64例316妇女月中的应用情况,说明其优点为放置时无痛苦,副反应、盆腔感染的发病率和带环妊娠的发生率均低,因此能被接受。

## **Intrauterine Adhesions: A Syndrome of the Past with the Use of the Massouras Duck's Foot No. 2 Intrauterine Contraceptive Device** 128

### **Massouras 鸭爪型2号宫内节育器对宫内粘连综合症的作用**

作者考虑到刮宫术后往往会产生子宫腔内粘连,引起术后月经少、闭经、自然流产与不孕症,所以设计了一种 Massouras 鸭爪2号宫内避孕器(MDF No. 2 IUCD),用于刮宫术后放置,可以避免上述症状的发生。MDF No. 2 IUCD 是一种软性聚乙烯或硅类器械,具一细的不锈钢丝埋存于其上支,以便于透视随访。所有的原材料均对人体无害。为了达到X线探测目的,可加入适量硫酸钡。节育器于宫颈扩张后放置。其两翼可产生适当重叠,以适应子宫腔的三角形,便于达到阻止宫腔内粘连或孕卵的着床。

## **Experience with the Dalkon Shield As A Contraceptive Device** 131

### **应用 Dalkon 盾作为宫内节育器的效果**

本文介绍 Dalkon 盾作为宫内节育器共291例,累积2143妇女月的资料。本组妇女使用这种节育器,每100妇女年中的妊娠率为10.1%,经过二年没有明显下降。说明这种装置还不如目前所采用的有效。由于受孕率高,故不宜继续使用。

## **Fertility Control by Intrauterine Release of Progesterone** 137

### **用黄体的宫内缓释来控制生育**

249名妇女为了避孕的目的,装置每天可释放128微克黄体的T形宫内节育器。6个月换一次新节育器。当装有有效黄体释放器的时期中,没有发现妊娠。选择一些病例进行血浆激素测定和子宫颈粘液的观察,都属正常范围,提示了带黄体节育器的机制与抑制排卵和改变宫颈粘液性质无关。结论是:极少量的宫内黄体是一种有效的避孕剂,其作用机制可能是引起子宫颈内膜感受器的蜕膜改变,使之不宜于着床。

## **The IUD & Prostaglandins: A Review of Evidence** 149

### **宫内节育器和前列腺素:对实验资料的评论**

有证据说明在某些非灵长类哺乳动物中,宫内节育器促使子宫增加前列腺素的释放。它的抗生育作用也许是通过前列腺素的溶解黄体作用。在灵长类动物,宫内节育器可能是由于子宫颈内膜前列腺素释放的增多,但显然没有对黄体直接抑制的作用。

## **Experience with a Fluid-filled Intrauterine Device** 153

### **灌液型宫内节育器**

作者报告了使用一种新式的充满液体的软性宫内节育器,由于放置与取除时,手术容易并且无痛,因此对未产妇也同样适用。由于其脱落率低,怀孕率等于零,副作用也极少,故为妇女所乐于接受的避孕措施。目前尚在进行扩大的临床使用中。

## **Serum Immunoglobulin Levels in Women Using Intrauterine Contraceptive Devices** 161

### **放置宫内节育器后妇女血清免疫球蛋白的水平**

由于节育器在宫腔内所引起的炎性反应,可能为节育器产生避孕作用的某些机制。在比较使用聚乙烯宫内节育器组(Lippes 环)与对照组时,Holub 等氏(1971年)发现血清IgG与IgM均有相当增加。本文对妇女放置不锈钢宫内节育器,于放置前、后进行了IgG, IgA与IgM的测定。在同一人身上进行测定,可以排除产生免疫球蛋白上升的其他非特异性的原因。IgA 常可作为粘膜面炎性反应的抗体,可惜在使用聚乙烯宫内节育器组中并未进行这一血清球蛋白的测定。本文的测定结果证实了IgG与IgM的增加,但约于一年后开始有下降趋向。在同一测定期间,血清IgA的水平逐渐上升。

## **Comparative Quantitation of Menstrual Blood Loss with the Lippes Loop, Dalkon Shield, & Copper T Intrauterine Devices** 167

### **放置 Lippes 氏环, Dalkon 氏盾,与T铜宫内节育器后妇女月经失血量的比较**

作者对放置 Lippes 氏环D,标准大小的Dalkon盾与T铜800的妇女,进行了月经失

血量的测定。测定时间为放置后 6、12 与 18 个月。放置节育器后平均月经失血量的增加为 41-112%。月经过多的发生率可达不放环对照组周期的 9 倍。在研究期间发现 Lippes 环与 Dalkon 盾两组的月经失血量不稳定,往往为不放节育器周期的一倍;而 T 铜 300 组的月经失血量在所有的观察期间相当稳定,且较其他两种避孕器的失血量为少。

#### Antifibrinolytic Control of Menorrhagia After IUD Insertion

177

##### 用抗纤维蛋白溶解酶来控制放置宫内节育器后的月经过多

本文作者引用了 Nilsson 和 Rybo, Kagan 等报导,由于子宫内膜浆活性物质使局部纤维蛋白溶解酶增加是月经过多的主要原因,用抗纤维蛋白溶解酶制剂氨基己酸能有效的减少月经量。作者于 1970 年 7 月起临床观察了 88 例放置宫内节育器的妇女,对其中 20 例主诉月经增多的用氨基己酸 3 克,每天四次的治疗,能减少月经量,有一例因恶心而停药。临床分析了年龄、产次及末次分娩到放置节育器的间隔对以后是否需要治疗没有关系。月经过多史是预测放置节育器后可能月经增多的唯一因素。

#### The in Site IUD & Pregnancy Outcome

182

##### 带宫内节育器受孕的后果

本文介绍了在 1971 年装置宫内节育器的 917 例中,46 例受孕的结果。研究对象是装置节育器后随访达 12 个月,除了脱落,取出及失访者外共 303 例,怀孕率为 15%。妊娠的发生是结合(1)宫内节育器的类型,(2)分娩与装置之间相隔的时间,(3)装置与受孕前的末次月经之间相隔的时间加以研究。妊娠的结果是从(1)自然中止妊娠时的妊娠月份,(2)产前后婴儿死亡率,(3)母体并发症方面进行分析。资料显示有不少妊娠是发生在产后装置节育器后。妊娠发生的时间不限于装置的初几个月。带有节育器受孕者的流产,产后感染和死胎率增高。

#### Antifertility Effects of an Intracervical Progestational Device

190

##### 宫颈管内放置孕激素节育器的抗生育效果

本文介绍宫颈内放置含有氯地孕酮的硅橡胶装置,目的在于观察是否此种装置比口服孕激素的剂量小且效果好。

在兔的实验中此种宫颈装置能影响受孕、着床和精子的运送。当此装置的氯地孕酮的释放率在 13.7~22.8  $\mu\text{g}/\text{公斤}/\text{天}$  时,则 100% 能避孕;在 2.4~7.0  $\mu\text{g}/\text{公斤}/\text{天}$  时不影响受孕;在 8.2~13.3  $\mu\text{g}/\text{公斤}/\text{天}$  的剂量尚有 47% 的卵子受孕。应用不能防止受孕的剂量亦能抑制着床。兔子在两次交配后 4 小时,有宫颈装置的子宫角中的精子数比对侧子宫角明显减少。

文内还介绍了三种用医用硅橡胶制的宫颈图钉型装置,分别含 15% 醋酸氯地孕酮、20% 醋酸氯地孕酮 100 mg 于 Sylold 中及作为对照的类固醇 30 mg。在月经周期第二周放置,初步估计释放率在 0.15 mg/天时,显示对宫颈粘液有反应,当释放率接近 1.6~2.1 mg/天时可伴随全身的影响,例如基础体温升高、宫内膜孕激素样变化和子宫出血等。

#### Physiological Aspects of Vaginal Contraception: A Review

197

##### 阴道避孕的生理学概念: 综述

阴道避孕剂在应用恰当时,是一种相当有效的避孕方法,这种避孕措施仍有潜力,但没有获得足够的重视。本文简单地评论关于目前使用的杀精子剂的某些方面,如性能、运载系统、剂型和效能等等以及将来有可能成为阴道避孕的有效制剂。强调了关于在人类中进行研究的资料。

#### Inhibition of Ovulation with Cyclic Use of Progestogen-Impregnated Intravaginal Devices

211

##### 周期性应用浸透孕激素的阴道节育器来抑制排卵

24 位妇女进行 10 个周期的研究以确定用浸透醋酸甲孕酮的塑胶阴道器的避孕效能、使用率和恢复率。治疗前她们都有 2 个推定证据的排卵周期作为对照。于月经第五天或第十天装置新的阴道器至第 26 天取出。治疗后随访 2 个周期。治疗期中,在黄体期血清孕酮没有上升,确定了排卵的抑制。用同样指标测定的排卵功能,一般在停药后第一周期恢复,很少有突破性出血。4 例有阴道小溃疡,取出避孕药后即自然愈合。第一次由医生装置后,用户可以自己装取而没有困难。这些研究提示,这种持续性给予类固醇的技术,有望成为避孕的一种方法。

# Reviews

# CURRENT DEVELOPMENTS

## Intrauterine contraception

HOWARD J. TATUM, M.D., P.H.D.

*New York, New York*

OVER THE past decade intrauterine devices have assumed an almost exponential increase in prominence as a method of providing safe and effective contraception. The intrauterine devices (IUD's) provide a method which has the attributes of combining a high degree of effectiveness and safety with simplicity and economy. It has the unique quality among reversible methods of contraception of providing long-term reduction in fertility by a single safe and relatively simple procedure. A chronologic history of the development and use of the IUD was presented by Southam<sup>1</sup> in 1964. I shall present here an outline of the evolutionary steps which depict the stages of transition of the IUD from its inception to the present, with some predictions as to its future role in human welfare.

The early history of IUD's is so poorly documented that the original concept has not been assigned to a person or in fact to a specific century. Early mention has been made of the use of stones placed within the endometrial cavity of camels to prevent pregnancy during long trips across deserts. Undoubtedly a similar method had been applied to women at or about the same time. These very early applications of the intrauterine foreign body as a means of regulating fertility

may be considered as the *embryonal stage* of evolution of intrauterine contraception. This stage was relatively void of true scientific study and knowledge of the subject.

The *infancy stage* of IUD evolution began in the 1920's with the ingenious and daring studies of Gräfenberg,<sup>2</sup> as reported in 1928. His first device consisted of a six-pointed star made by tying three pieces of silkworm-gut together at the center (Fig. 1, A). Initially the central tie was of silkworm gut also. Gräfenberg soon found that he could not easily detect the presence of the star within the uterine cavity by means of a probe or sound. He attempted to correct this structural deficiency by substituting a center tie made of thin silver wire for one of gut (Fig. 1, B). The wire permitted detection with the uterine probe, and also rendered the star partially radiopaque. The star was so soft, however, that it was readily expelled from the uterus. Although the star has a relatively low retention rate, Gräfenberg thought that the silver-bound device was somewhat more effective as a contraceptive than the original silver-free star. In order to increase the retention rate, Gräfenberg conceived of and made the first intrauterine ring. This device consisted of several turns of silkworm-gut making a ring approximately 2 cm. in diameter having a cross section of about 2 mm. (Fig. 2, A). The rings were then made more rigid as well as radiopaque by binding them

*From the BioMedical Division, The Population Council, The Rockefeller University.*

with fine silver wire (Fig. 2, B). Although this silver bound gut ring was found by Gräfenberg to be highly effective, it was soon replaced by a ring made by joining the two ends of a tightly wound spiral of silver wire (Fig. 2, C). The spirally wound ring possessed moderate spring properties, and hence could be compressed into a smaller and oblong configuration for insertion through the cervical canal. Its inherent resiliency then caused it to return to the original circular ring shape when it was released within the more spacious endometrial cavity. This model of the Gräfenberg ring was inserted by him into several thousand women and was the first intrauterine device commercially manufactured. Gräfenberg first reported the results of his clinical experiences in 1928. His work attracted much interest from the medical profession and almost uniform condemnation by the obstetricians and gynecologists. The criticism primarily was based upon the occurrence (or recurrence) of endometritis and salpingitis subsequent to the introduction of the ring. Little consideration was taken of the high incidence of pelvic inflammatory disease which prevailed at the time. Thus, much of the criticism which was directed toward Gräfenberg and against the intrauterine ring was based more upon the conservative traditionalism of the gynecologist than upon scientifically valid reasons. It was indeed a tragedy that conservatism prevailed since the traditional taboo against inserting a foreign body into the uterine cavity thwarted the advance of contraceptive technology for at least 30 years.

During the same decade that Gräfenberg began his epoch-making studies, Ota<sup>3</sup> in Japan was working independently on intrauterine devices. Ota initially used silkworm-gut rings, and then developed small rings fabricated from flexible metals. Although the metal rings seemed to provide more effective contraception than did the gut rings, they were more difficult to insert. For this reason, Ota and his disciples in Japan directed their development toward rings fabricated from various synthetic plastics (Fig. 3).

The 30 year infancy stage of IUD's as




Fig. 1. A, Gräfenberg star, all silkworm-gut. B, Gräfenberg star, center tie of "silver" wire.

depicted by the works of Gräfenberg and Ota ended when the significance of their pioneering studies was finally realized. Appreciation of their contributions came in 1959 with the papers by Ishihama<sup>4</sup> in Japan and Oppenheimer<sup>5</sup> in Israel. A major step in opposition to the traditional objections against the use of intrauterine devices was taken by Dr. Howard C. Taylor who in 1959 was Editor of the *AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY*. Acting on behalf of the Editorial Board of the *JOURNAL*, Dr. Taylor invited Oppenheimer to submit for publication a review of his clinical experiences with the Gräfenberg ring. This paper was the first detailed clinical evaluation of intrauterine contraception ever published by an American scientific journal. Both Ishihama and Oppenheimer reported corroborating data on the long-term use of various intrauterine rings. With these independent and impressive demonstrations of effectiveness and safety of the intrauterine foreign body, the IUD entered its *childhood stage*. The *childhood stage* began between 1959 and 1964, when Margulies<sup>6</sup> (Fig. 4), Zipper and Sanhuerza<sup>7</sup> (Fig. 5), Lippes<sup>8</sup> (Fig. 6), Birnberg and Burnhill<sup>9</sup> (Fig. 7), Hall<sup>10</sup> (Fig. 8), among many others in the United States and abroad, designed and tested various forms of intrauterine contraceptive devices.

In 1962, The Population Council launched an intensive research program which included relevant basic laboratory studies and clinical and field trials with promising IUD's.<sup>11</sup> The data derived from these clinical studies




Fig. 2. A, Gräfenberg ring—all silkworm-gut. B, Gräfenberg ring—silkworm-gut wound with "silver" wire. C, Gräfenberg ring—tightly wound spiral of "silver" wire.




Fig. 3. Ota ring.

were evaluated by the Cooperative Statistical Program (C.S.P.) under the direction of Dr. Christopher Tietze. The most recent report on traditional IUD's by the C.S.P., as of 1968,<sup>12</sup> covers approximately 547,000 woman-months of use by almost 32,000 women. This extensive experience, particularly with the Lippes loop led the IUD into its *adolescence*. During the 6 years from 1962 to 1968, the loop was used more extensively than any other device. Because of the wide clinical experience with and the comprehensive evaluation of the loop, it became customary to use these data as points of reference in evaluating the clinical effectiveness (also referred to as use effectiveness) of newly conceived shapes and sizes of intrauterine devices.<sup>13</sup> The term clinical, or use effectiveness, is of fundamental importance and has been accurately defined by these authors as follows: "Use effectiveness, also known as clinical effectiveness, refers to the protection from unwanted pregnancy achieved by users under real life conditions, including the effects of carelessness, ambivalence, and other manifestations of human frailty."<sup>14</sup> According to the latest analysis of data derived




Fig. 4. Margulies spiral.

predominantly from studies within the United States, the failure rate (pregnancy rate) per 100 users of Loop D for the first year is 1.9, decreasing to 1.6 at 2 years, and to 1.2 at the end of 4 years. On the other hand, the use effectiveness or continuation rate in the C.S.P. clientele ranged from 70 to 80 per cent of the users at the end of the first year and 60 to 70 per cent 2 years after the first insertion. Continuation rates derived from national family planning programs outside of the United States are on the order of 50 per cent after 2 years of use.<sup>15</sup> From these standards, we can assume that racial, environmental, and socioeconomic factors play an




Fig. 5. Zipper (Gräfenberg) ring.




Fig. 6. Lippes loop.




Fig. 7. Birnberg bow.




Fig. 8. Hall ring.

important although undefined role in determining the use effectiveness of an intra-uterine device. Also the necessity of establishing statistically valid control population samples becomes self evident.

Although a wide variety of new devices were constructed from synthetic plastics, stainless steel, silicone rubber, and silkworm-gut, the associated side effects, such as bleeding, spotting, uterine cramps, lower abdominal pain, and noticed or unnoticed expulsion, resulted in growing dissatisfaction on the part of women and the medical profession. For the Lippes loop Size "D," these side effects may be translated to a discontinuation rate of 23 per cent at the end of the first year of use, and 35 per cent after 2 years of use. From a demographic viewpoint, this level of use effectiveness is discouraging, and pointed

up the need to develop devices which could have more efficient performance. Thus the *adolescent stage* ended with a challenging mandate for improvement.

In 1966, the author concluded that most if not all of the IUD's then in use shared one common deficiency. Each device by virtue of its shape and over-all dimensions forced the endometrial cavity to *adjust to the configuration of the device*. As a result, the delicate endometrium is *compressed* and the myometrium is *distended*. This frequently results in bleeding from the endometrial surfaces as well as painful contractions as the myometrium reacts to oppose its distention and to expel the foreign body which has been placed within its cavity.

A logical sequence to this hypothetical consideration was to determine the shape and size of a foreign body which *would conform to the endometrial cavity and would thereby cause a minimum degree of distur-*




Fig. 9. Interlacing network of myometrial fibers.

tion, even at the height of a uterine contraction. The concept that an intrauterine contraceptive device should conform to the endometrial cavity *rather* than the *cavity* and myometrium being obliged to conform to the device, may be considered as the beginning of the *pubescent stage* of IUD development or evolution.

Consideration of certain anatomic factors and functional characteristics of the human uterus are essential requisites to progression from a philosophical concept to practical application. It seems appropriate at this point to discuss the more obvious of these factors. When the endometrial cavity is empty, the mucosal surfaces are separated only by a thin film of mucus and other secretions of the endometrial glands and tubal epithelium. The size and shape of the potential cavity depend upon the contractile state of the myometrium. Only when the walls of the uterus are distended is there an actual endometrial cavity with true spatial characteristics. Fig. 9 represents the directions and interlacing network of muscle fibers which control the size and shape of the uterus. The configuration and size of the endometrial cavity normally reflect the summation of myometrial forces. Fig. 10, *A* to *C* indicates progressive changes in the uterine wall and its cavity with increasing degrees of contraction. The walls thicken and shorten, and the cavity responds by becoming smaller in all dimensions. As the contraction increases, the lateral walls of the cavity

approximate one another, and the cavity or potential space assumes the shape of a T. The assumption was made that this T-shaped configuration would persist even when the uterus contracted maximally. Based upon these theoretical considerations, it was logical to presume that an intrauterine foreign body in the shape of a T could be placed within the endometrial cavity and would conform *easily* to the normal shape and size of the cavity, and would cause a minimum degree of myometrial distension and endometrial compression. Fig. 11 illustrates this concept. Fig. 12 shows in diagrammatic form the sequential changes in the *uterine walls and its cavity* during several degrees of contraction, and indicates the relative conformity of the T-shaped device to the uterine cavity. This principle was tested in 1967 when the first T was molded from a mixture of polyethylene and barium sulfate and was tested clinically by Tatum and Zipper.<sup>16</sup> An example of the T is shown in Fig. 13. Its spatial relationship to the endometrial cavity is shown in diagrammatic form in Fig. 11. The preliminary clinical data showed that the T produced about  $\frac{1}{5}$  the incidence of pain and bleeding as did the Lippes loop "D." The expulsion rate was approximately half that of the loop.

The low incidence of expulsion is presumably due to two distinct features. The T conforms so well to the uterine cavity that the myometrium is subjected to only minimal distortion. Second, displacement and rotation of the T within the uterine cavity is resisted by the three points of contact between the device and the uterine walls which contain it. In effect, the T is suspended within the endometrial cavity by impingement of the tips of the two transverse arms against the superficial layers of the endometrium. The low incidence of pain, bleeding, and expulsion were in accordance with the theoretical considerations upon which the T was based. However, the low incidence of side effects was accompanied by a low level of contraceptive effectiveness. At the end of one year the pregnancy rate was approximately 18 per cent. Thus, although the




Fig. 10, A to C. Diagrammatic changes in endometrial cavity during sequential degrees of myometrial contraction.




Fig. 11. Relationship between the T and endometrial cavity at the height of uterine contraction.

T was tolerated well by the uterus, it was unacceptable as a contraceptive when used alone. It is likely that the small surface area of the T (approximately 315 mm.<sup>2</sup>) explains its relatively low contraceptive effect.

In an independent study, Davis and Israel<sup>17</sup> computed the average dimensions of the endometrial cavity at several levels from the intercornual plane downward toward the internal cervical os. These dimensions are summarized schematically in Fig. 14. Based upon these measurements, and upon the premise postulated by Zipper and associates<sup>18</sup> that the antifertility effect of an "inert" IUD bears a direct relationship to the surface area of contact between the IUD and the endometrium, Davis<sup>19</sup> designed a device which he named the "Shield" (Fig. 15). This device is slightly pear-shaped, and




Fig. 12. Sequential changes in endometrial cavity during a uterine contraction.

its retention within the uterine cavity is enhanced by the presence of spicular projections along its lateral margins. Although the cephalocaudal and transverse dimensions of the shield are considerably smaller than those of Lippes loop "D," the total surface of the device is greater due to a thin membrane which partially covers the shield. Preliminary clinical data on the shield<sup>19</sup> suggest that its antifertility effect is considerably better than the 18 per cent pregnancy rate achieved by the plain T. It is logical to assume that the difference may be related to the disparity between surface areas of the two devices. It has been postulated that implantation may be jeopardized when normally opposing endometrial surfaces are separated by an